Literature DB >> 15467433

Mismatch repair gene expression and genetic instability in testicular germ cell tumor.

Alfredo Velasco1, Erick Riquelme, Marcela Schultz, Ignacio I Wistuba, Luis Villarroel, Javier Pizarro, Alejandro Berlin, Michael Ittmann, Moon S Koh, Fredrick S Leach.   

Abstract

Human mismatch repair (MMR) genes encode highly conserved interacting proteins that correct replication errors predisposing to hereditary gastrointestinal and genitourinary malignancies. A subset of sporadic genitourinary tumors also exhibits MMR deficiency and can be identified by measuring the frequency of microsatellite instability (MSI) in cancer cell DNA. We investigated expression of the two most commonly mutated MMR genes, MSH2 and MLH1, in sporadic testicular germ cell tumor (GCT) in order to: (1) determine the expression pattern of MSH2 and MLH1 proteins in normal seminiferous tubules and histologically distinct GCT subtypes, (2) correlate MMR gene expression with genetic instability in GCT and (3) develop a panel of molecular markers that can identify genetically distinct subsets of GCT for prognostic assessment. MSH2 and MLH1 had differential staining patterns in normal seminiferous tubules and malignant tissues. MSH2 was expressed in all stages of spermatogenesis up to but excluding mature sperm whereas MLH1 was predominantly expressed in premeiotic germ cells. All histological GCT subtypes showed differential immunostaining for MSH2 and MLH1 however pure seminoma had statistically significant fewer low MSH2 staining tumors than other subtypes (p = 0.046). Twenty-five percent of GCT exhibited increased frequency of MSI (MSI+ tumors) with 73, 70 and 43% of MSI+ tumors exhibiting low MSH2, low MLH1 or low MSH2 and low MLH1 staining respectively. Fifteen percent of testicular GCT exhibited loss of heterozygosity (LOH) but no MSI (LOH only tumors). Only 28, 17 or 6% of LOH only tumors exhibited low MSH2, low MLH1 or low MSH2 and low MLH1 staining respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467433     DOI: 10.4161/cbt.3.10.1135

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  5 in total

1.  Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.

Authors:  Christiane Rudolph; Cecilie Melau; John E Nielsen; Kristina Vile Jensen; Dekang Liu; Javier Pena-Diaz; Ewa Rajpert-De Meyts; Lene Juel Rasmussen; Anne Jørgensen
Journal:  Cell Oncol (Dordr)       Date:  2017-05-23       Impact factor: 6.730

Review 2.  Overcoming Chemotherapy Resistance in Germ Cell Tumors.

Authors:  Zuzana Országhová; Katarina Kalavska; Michal Mego; Michal Chovanec
Journal:  Biomedicines       Date:  2022-04-22

3.  Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.

Authors:  Miguel F Sanmamed; E Esteban; E Uriol; R Zarate; M Capelan; C Muriel; G Crespo; J P Berros; P Pardo-Coto; Q Perez; C Alvarez-Fernández; P Jiménez Fonseca; M Luque; A Astudillo
Journal:  J Transl Med       Date:  2017-03-20       Impact factor: 5.531

4.  Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.

Authors:  João Lobo; Ângelo Rodrigues; Rita Guimarães; Mariana Cantante; Paula Lopes; Joaquina Maurício; Jorge Oliveira; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2019-10-11       Impact factor: 6.639

5.  Cell cycle analysis of fetal germ cells during sex differentiation in mice.

Authors:  Cassy Spiller; Dagmar Wilhelm; Peter Koopman
Journal:  Biol Cell       Date:  2009-07-31       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.